Press release
Investigation for NASDAQ: OSMT Investors announced over potential Wrongdoing at Osmotica Pharmaceuticals plc
An investigation on behalf of investors in Osmotica Pharmaceuticals plc (NASDAQ: OSMT) shares over potential wrongdoing.
Investors who purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Osmotica Pharmaceuticals plc (NASDAQ: OSMT officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Bridgewater, NJ based Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. Osmotica Pharmaceuticals plc reported that its annual Total Revenue rose from $245.74 million in 2017 to $263.7 million in 2018 and that its Net Loss increased from $41.14 million in 2017 to $109.39 million in 2018.
On March 27, 2019, after the markets closed, Osmotica Pharmaceuticals plc announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change.
Those who purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for NASDAQ: OSMT Investors announced over potential Wrongdoing at Osmotica Pharmaceuticals plc here
News-ID: 1896245 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Osmotica
Parkinson's Disease Market Development and Research by Acorda Therapeutics, Inc, …
This Parkinson's Disease Market analysis report also offers a list of the chief competitors and provides the strategic insights and analysis of the key factors influencing the industry. All statistical and numerical data is interpreted with the use of established and advanced tools such as SWOT analysis and Porter's Five Forces Analysis. This Parkinson's Disease Market business document is built with the careful efforts of an innovative, enthusiastic, knowledgeable, and…
Latest Analysis of Acquired Blepharoptosis Market Pipeline Insight-: How the Bus …
In The Acquired Blepharoptosis Market Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Acquired Blepharoptosis Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.
Get a sample copy of the report at- https://www.marketreportsworld.com/enquiry/request-sample/14376773
The Report Provides Insights Into:
o All Of The Companies That Are Developing Therapies For The…
Investigation announced for Investors in shares of Osmotica Pharmaceuticals plc …
An investigation was announced over potential securities laws violations by Osmotica Pharmaceuticals in connection with certain financial statements.
Investors who purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Osmotica Pharmaceuticals plc regarding its business, its prospects and its operations were materially…
Parkinson’s Disease Market Share, Growth Strategy With Teva Pharmaceutical, I …
The market research report provides up-to-date parkinson’s disease market information which could assist readers with hands-on information expected to settle on brisk choices anytime during their development venture in the market. The report offers parkinson’s disease market presentation, major overview, goals, market definition, extension, and market size estimation. A definite clarification of market values, potential buyers and the future degree are exhibited in this report. This parkinson’s disease report incorporates…
Spasticity Therapeutics- Pipeline Analysis 2018 | Top Player are Osmotica Pharma …
Spasticity is a condition in which certain muscles are continuously contracted. The constant muscle contraction causes stiffness or tightness of the muscles and can interfere with normal movement, speech and gait in a patient.
Download the sample report @ https://www.pharmaproff.com/request-sample/1088
Spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement. This damage causes a change in the balance of signals between the nervous…
3D Printed Drugs Market 2018 Analysis by Segment, Top Leading Companies are (Apr …
The Global 3D Printed Drugs Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Growing usuage of 3D printing and increasing adoption of personalized drugs are the potential factor for the growth of this market.
Growth in 3D printed drugs market is driven by the factors like rising health related and growing population across the globe.
Increase in healthcare investment…
